ClinicalTrials.gg
CompletedNCT05829850Updated Apr 26, 2023

An Effectiveness and Safety 6 Months Study of 3 Injections One Week Apart of SYNOLIS VA 40/80 in the Treatment of Symptomatic Knee Osteoarthritis

An interventional study of SYNOLIS VA 40/80 in Osteo Arthritis Knee, sponsored by Aptissen SA. Completed at 3 sites in Poland. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-26.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's title name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aptissen SA · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Dec 2021, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.

Enrollment
64th of 72
51 · median 115
Started
2021
with 5 others
No phase
28 of 78
9 open now
Registered
44th of 78
by date
Lead sponsor
2 of 78
Aptissen SA

Among the 78 studies in Osteoarthritis, Knee with a site in Poland, this one is the 64th largest by enrollment of the 72 interventional ones that give a count, is one of 6 that started in 2021, is one of 28 with no phase, and was the 44th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 78 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Osteoarthritis, Knee with a site in Poland, or all of them as a file.
02

Study summary

Multicentre, independent assessment study on SYNOLIS VA 40/80 over a period of 24 weeks

03

Conditions studied

  • Osteo Arthritis Knee

Browse trials for

Keywords

  • Osteoarthritis
  • Knee Osteoarthritis
  • Hyaluronic acid
04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 51 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Aptissen SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient between 35 and 75 years old
  • Patients with knee osteoarthritis. The diagnosis is based on the following American College of Rheumatology (ACR) classification:

    • Knee pain
    • Positive radiography (presence of osteophytes)
    • Morning stiffness \< 30 min and/or crepitus while walking
  • Symptoms related to knee osteoarthritis for at least 6 months
  • Treatment failure (i.e. ineffective response) with analgesics and/or NSAIDs or intolerance to NSAIDs or low-grade opioids
  • Kellgren-Lawrence radiographic stage: I - III (pre-inclusion radiography)
  • VAS pain index score ≥ 40 mm (VAS 0-100 mm) on the knee to be treated
  • Contralateral knee pain \< 10 mm (VAS) compared to treated knee
  • Patient signed inform consent form

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the study or language used to be informed/sign the consent
  • Participation in another clinical trial within 4 weeks prior to the start of the trial, and commitment to non-participation within 4 weeks following the end of the trial
  • Intraarticular injection of hyaluronic acid in target knee within the 6 months prior to inclusion
  • Patient who has received an intra-articular (IA) or intra-muscular (IM) injection within the 3 months prior to inclusion or has taken oral corticosteroids within the month prior to inclusion
  • Joint, bone, ligament, or any local or loco-regional surgery of the leg involved, arthroscopic operation on the target knee within the 3 months prior to inclusion
  • Any recent trauma to the leg involved, including a sprain, dislocation within the 3 months prior to inclusion
  • Rheumatoid arthritis, joint condition or any other inflammation and arthritis
  • Lupus
  • Dermatological disorder or any epidermal conditions that prevent an intraarticular injection
  • Visible remarkable joint effusion of the target knee during physical examination evidenced by a protuberance or positive ballottement of the patella
  • Evidence of a subchondral fracture, meniscal lesion, presence of bone or cartilage fragments, horizontal meniscal lesion tear (FLAP) in the target knee
  • Osteonecrosis (1 or both knees)
  • Daily dosage > 101 mg of acetylsalicylic acid as part of cardiovascular preventive treatment (antithrombotic). If dose \< 101 mg, must be maintained during the study
  • Known intolerance//allergy to any of the components in either product, SYNOLIS VA
  • Fibromyalgia
  • Patient of , pregnant or breast-feeding known at inclusion or in the planning phase during the study unless willing to use through the whole duration of the study
  • Excessive and repeated consumption of alcohol or illicit substances
  • Any medical condition that may interfere with the proper conduct of the study (including any surgery or hospitalisation)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    SYNOLIS VA 40/80

    SYNOLIS VA 40/80 (hyaluronic acid 40 mg, sorbitol 80 mg), intra-articular injection

    Device: SYNOLIS VA 40/80

Interventions

  • DeviceSYNOLIS VA 40/80

    Three 2mL injections of SYNOLIS VA 40/80, one week apart

07

What researchers measure

Primary outcomes

  1. Difference in total Western Ontario and McMaster Universities Arthritis index (WOMAC) score total between D168 and inclusion visit.

    The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)

    Time frame: 168 days

Secondary outcomes

  1. Change in pain measurements, assessed using the Western Ontario and McMaster Universities Arthritis (WOMAC) pain severity index, as compared to D0

    The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)

    Time frame: up to 168 days

  2. Change in the Western Ontario and McMaster Universities Arthritis (WOMAC) functional severity index, as compared to D0

    The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)

    Time frame: up to 168 days

  3. Change in the Western Ontario and McMaster Universities Arthritis (WOMAC) stiffness severity index, as compared to D0

    The Western Ontario and McMaster Universities Arthritis index (WOMAC) is a 24-item, condition-specific questionnaire available in a 5-point Likert and 100 mm visual analog scale (VAS) as well as an 11-box numerical rating scale, composed of three subscales: pain (5 questions), stiffness (2 questions) and physical function (17 questions). VAS was used in this study, with a score of 0 for no pain and 100 mm for the worst pain one can image)

    Time frame: up to 168 days

  4. Pain at walking on a 100 mm VAS

    Time frame: up to 168 days

  5. Percentage of subjects using analgesics

    New NSAID / analgesics drugs usage

    Time frame: up to 168 days

  6. Measurement of relief satisfaction by the patient

    7-point Likert scale (1 point very unsatisfied to 7 points for very satisfied)

    Time frame: 168 days

  7. Measurement of therapeutic efficacy by the investigator (assessor)

    7-point Likert scale (1 point very unsatisfied to 7 points for very satisfied)

    Time frame: 168 days

Other outcomes

  1. Safety and tolerability of SYNOLIS VA 40/80 assessed with adverse events monitoring throughout the study duration

    Time frame: 168 days

08

Study locations

3 sites
  • Carolina Medical Center
    Warszawa, 02-757, Poland
  • SPORTO oddzial na ulicy Miedzianej
    Łódź, 09-038, Poland
  • SPORTO oddzial na ulicy Książka (2nd site location)
    Łódź, 91-603, Poland
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2023, 12 months.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 12 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 26, 2023
StartActual
Dec 29, 2021
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Last update
Apr 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05829850
Lead sponsor
Aptissen SA
Collaborators
Noblewell
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
Dec 29, 2021
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Last update
Apr 26, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion